By -

Epicutaneous Immunotherapy May Provide Lasting Protection Against Anaphylaxis

New preclinical data from DBV Technologies is suggesting Epicutaneous Immunotherapy (EPIT) provides sustained protection against food-induced anaphylaxis — both during therapy and after treatment.   This is huge news for families with food allergies because it’s the first time this skin-gut immune communication has been proven to suppress anaphylaxis even after treatment has ended. The goal of Epicutaneous Immunotherapy is...